These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 19140204)
1. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886 [TBL] [Abstract][Full Text] [Related]
6. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360 [TBL] [Abstract][Full Text] [Related]
7. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073 [TBL] [Abstract][Full Text] [Related]
8. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Weber JS; Samlowski WE; Gonzalez R; Ribas A; Stephenson J; O'Day S; Sato T; Dorr R; Grenier K; Hersh E Cancer; 2010 Aug; 116(15):3683-91. PubMed ID: 20564083 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 plus chemotherapy for patients with metastatic melanoma. Paciucci PA; Ryder JS; Mandell JP; Morris JC; Holland JF Melanoma Res; 2000 Jun; 10(3):291-5. PubMed ID: 10890384 [TBL] [Abstract][Full Text] [Related]
10. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801 [TBL] [Abstract][Full Text] [Related]
11. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; MartÃn JA; Lardelli P Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178 [TBL] [Abstract][Full Text] [Related]
13. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients. Atzpodien J; Morawek L; Fluck M; Reitz M Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537 [TBL] [Abstract][Full Text] [Related]
14. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Powell S; Dudek AZ Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971 [TBL] [Abstract][Full Text] [Related]
16. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326 [TBL] [Abstract][Full Text] [Related]
17. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Tarhini AA; Kirkwood JM; Tawbi H; Gooding WE; Islam MF; Agarwala SS Cancer; 2008 Mar; 112(5):1131-8. PubMed ID: 18286511 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884 [TBL] [Abstract][Full Text] [Related]
20. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]